Algert Global LLC Makes New $213,000 Investment in Vericel Co. (NASDAQ:VCEL)

Algert Global LLC bought a new stake in Vericel Co. (NASDAQ:VCEL) in the 2nd quarter, Holdings Channel.com reports. The fund bought 4,632 shares of the biotechnology company’s stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in VCEL. Congress Asset Management Co. MA increased its position in Vericel by 509.1% in the first quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock worth $43,514,000 after purchasing an additional 699,147 shares during the period. TimesSquare Capital Management LLC bought a new stake in shares of Vericel during the first quarter worth approximately $12,782,000. Federated Hermes Inc. lifted its holdings in Vericel by 34.9% in the second quarter. Federated Hermes Inc. now owns 840,787 shares of the biotechnology company’s stock valued at $38,575,000 after buying an additional 217,437 shares during the period. Victory Capital Management Inc. boosted its stake in Vericel by 51.5% in the second quarter. Victory Capital Management Inc. now owns 611,146 shares of the biotechnology company’s stock valued at $28,039,000 after acquiring an additional 207,714 shares during the last quarter. Finally, Geneva Capital Management LLC grew its holdings in Vericel by 43.6% during the 1st quarter. Geneva Capital Management LLC now owns 679,165 shares of the biotechnology company’s stock worth $35,330,000 after acquiring an additional 206,202 shares during the period.

Vericel Stock Down 2.1 %

Shares of NASDAQ:VCEL opened at $40.09 on Friday. The firm has a market cap of $1.95 billion, a price-to-earnings ratio of -4,009.00 and a beta of 1.67. Vericel Co. has a 12 month low of $30.18 and a 12 month high of $54.10. The company’s fifty day simple moving average is $45.97 and its 200 day simple moving average is $47.18.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, meeting analysts’ consensus estimates of ($0.10). The company had revenue of $52.70 million for the quarter, compared to analyst estimates of $52.59 million. Vericel had a return on equity of 0.35% and a net margin of 0.37%. The company’s quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) earnings per share. Research analysts expect that Vericel Co. will post 0.12 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on VCEL. BTIG Research reduced their price target on Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a research report on Monday, July 15th. Stephens boosted their target price on Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. TD Cowen increased their price target on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. StockNews.com cut shares of Vericel from a “hold” rating to a “sell” rating in a report on Tuesday. Finally, Canaccord Genuity Group began coverage on shares of Vericel in a report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock. One analyst has rated the stock with a sell rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $55.75.

Insiders Place Their Bets

In other news, Director Steven C. Gilman sold 5,833 shares of Vericel stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total value of $235,361.55. Following the sale, the director now directly owns 11,000 shares in the company, valued at $443,850. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Vericel news, insider Sean C. Flynn sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $52.18, for a total transaction of $782,700.00. Following the transaction, the insider now owns 707 shares of the company’s stock, valued at $36,891.26. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total transaction of $235,361.55. Following the transaction, the director now owns 11,000 shares in the company, valued at approximately $443,850. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,333 shares of company stock valued at $1,917,562 in the last quarter. 5.20% of the stock is currently owned by insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.